Ascendiant Capital Maintains Buy on Outlook Therapeutics, Lowers Price Target to $33
Portfolio Pulse from Benzinga Newsdesk
Ascendiant Capital has maintained a Buy rating on Outlook Therapeutics but lowered the price target from $35 to $33.
September 03, 2024 | 10:16 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Ascendiant Capital maintains a Buy rating on Outlook Therapeutics but reduces the price target from $35 to $33, indicating a slightly less optimistic outlook.
The maintained Buy rating suggests continued confidence in the stock, but the lowered price target indicates a slightly less optimistic view on its potential upside. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100